Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trastuzumab Deruxtecan in ctDNA+ HER2+ Gastrooesophageal Adenocarcinoma
NCT05965479Phase 2Recruiting
- Sponsor
- University of Southampton
- Start
- Apr 2024
- Primary completion
- Mar 2026
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of trastuzumab deruxtecan in gastroesophageal adenocarcinoma, sponsored by University of Southampton. Started Apr 2024; status: recruiting.
02
Drugs
trastuzumab deruxtecan
03
Conditions
gastroesophageal adenocarcinoma
Beyond the preview
Go deeper on NCT05965479.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05965479.